Anbio Biotechnology (NNNN) Operating margin 2022–2025
Anbio Biotechnology (NNNN) operating margin by fiscal year — reported operating income divided by reported revenue.
66.7%FY2025 · since FY2022: 43.3% → 66.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 66.7% | +42.3 pp |
| FY2024 | 24.4% | -4.8 pp |
| FY2023 | 29.2% | -14.1 pp |
| FY2022 | 43.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NNNN financial trends
NNNN RevenueNNNN Net incomeNNNN Net marginNNNN Gross profitNNNN Gross marginNNNN Operating incomeNNNN Operating cash flowNNNN Free cash flowNNNN Capital expendituresNNNN Return on equityNNNN Stock buybacksNNNN Dividends paidNNNN Total assetsNNNN Total liabilitiesNNNN Shareholders’ equityNNNN overview →